Scarica l'app Stockscreener
1.33
0.76%
0.01
Precedente Chiudi:
$1.32
Aprire:
$1.31
Volume 24 ore:
239.69K
Relative Volume:
0.49
Capitalizzazione di mercato:
$59.68M
Reddito:
$19.94M
Utile/perdita netta:
$-37.37M
Rapporto P/E:
-1.2788
EPS:
-1.04
Flusso di cassa netto:
$-33.38M
1 W Prestazione:
+13.68%
1M Prestazione:
+1.53%
6M Prestazione:
-10.74%
1 anno Prestazione:
-34.16%
Intervallo 1D:
$1.25
$1.40
Intervallo di 1 settimana:
$1.15
$1.40
Portata 52W:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Nome
Werewolf Therapeutics Inc
Settore
Industria
Telefono
617-952-0555
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Confronta HOWL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.33 | 59.23M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-24 | Iniziato | Wedbush | Outperform |
| 2023-06-06 | Ripresa | Jefferies | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-25 | Iniziato | Evercore ISI | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-25 | Iniziato | Jefferies | Buy |
| 2021-05-25 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
Custom watchlist performance reports with Werewolf Therapeutics Inc.2025 Market Outlook & Daily Stock Momentum Reports - Newser
Using data filters to optimize entry into Werewolf Therapeutics Inc.Market Trend Review & Community Verified Watchlist Alerts - Newser
When is the best time to exit Werewolf Therapeutics Inc.2025 Year in Review & Proven Capital Preservation Tips - Newser
Why Werewolf Therapeutics Inc. is moving today2025 Market Overview & Fast Moving Market Watchlists - Newser
Smart tools for monitoring Werewolf Therapeutics Inc.’s price actionGap Up & Community Consensus Stock Picks - Newser
Real time alert setup for Werewolf Therapeutics Inc. performanceBond Market & Capital Efficiency Focused Ideas - Newser
What recovery options are there for Werewolf Therapeutics Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Is Werewolf Therapeutics Inc. backed by strong institutional buyingWeekly Earnings Recap & Smart Investment Allocation Insights - sundaytimes.kr
Using data models to predict Werewolf Therapeutics Inc. stock movementJobs Report & Technical Pattern Based Buy Signals - Newser
Is Werewolf Therapeutics Inc. meeting your algorithmic filter criteriaTrend Reversal & Weekly Setup with High ROI Potential - Newser
Werewolf Therapeutics reports Q2 EPS (40c), consensus (37c) - MSN
Werewolf Therapeutics Reports Q2 2025 Financial Results - MSN
Werewolf Therapeutics Inc. stock momentum explained2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Published on: 2025-08-15 16:22:03 - Newser
Can swing trading help recover from Werewolf Therapeutics Inc. lossesQuarterly Trade Report & AI Forecasted Entry and Exit Points - Newser
Werewolf Therapeutics Reports Q2 EPS of -$0.40, Beating Estimates - AInvest
Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions - TipRanks
Is Werewolf Therapeutics Inc. in a bullish channel2025 Dividend Review & Free Risk Controlled Daily Trade Plans - sundaytimes.kr
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Reports No Revenue in Fiscal Q2 - The Motley Fool
Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView
Werewolf Therapeutics: Capitalizing on Immuno-Oncology Innovation with a Strategic Path to Commercialization - AInvest
Cancer Drug Developer Werewolf Sets Q4 Melanoma Trial Readout, Unveils New Prostate Cancer Program - Stock Titan
Using economic indicators to assess Werewolf Therapeutics Inc. potential2025 Bull vs Bear & Precise Swing Trade Entry Alerts - Newser
Relative strength of Werewolf Therapeutics Inc. in sector analysisJuly 2025 Big Picture & Safe Entry Momentum Tips - Newser
Key metrics from Werewolf Therapeutics Inc.’s quarterly dataQuarterly Trade Summary & Trade Opportunity Analysis Reports - Newser
Published on: 2025-08-13 22:40:57 - 선데이타임즈
Understanding Werewolf Therapeutics Inc.’s price movementMarket Rally & Free Community Supported Trade Ideas - Newser
Analyzing Werewolf Therapeutics Inc. with risk reward ratio chartsAI-Based Signal Detection for Active Traders - Newser
Visual analytics tools that track Werewolf Therapeutics Inc. performanceQuarterly Earnings Summary & Community Supported Trade Ideas - Newser
Analyzing Werewolf Therapeutics Inc. with multi timeframe chartsStrong Buy Opportunity with Volume Support - Newser
How institutional ownership impacts Werewolf Therapeutics Inc. stockLong Term Stock Planner with Safety Checks - Newser
Short interest data insights for Werewolf Therapeutics Inc.Free Smart Allocation Stock Pick Insights - Newser
Strategies to average down on Werewolf Therapeutics Inc.Free Swing Trade Entry With Volume Triggers - Newser
Using Python tools to backtest Werewolf Therapeutics Inc. strategiesLong-Term Allocation Strategy Summary Breakdown - Newser
Full technical analysis of Werewolf Therapeutics Inc. stockBuy Zone Strategy with Pattern Recognition - Newser
Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):